Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIVATE study of BIA 28-6156 in GBA1-associated Parkinson's disease
NL-OMON59922Phase 2Completed
- Sponsor
- BIAL
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing BIA 28-6156 with Placebo (2 arms). Primary endpoint: Time to clinically meaningful motor progression based on MDS-UPDRS Part II and Part III. Started Apr 2024; status: completed.
02
Drugs
pariceract
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON59922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59922.